Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu

Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu

Item

http://www.wikidata.org/entity/Q33517581

Q33517581

about

Synergy of Streptogramin Antibiotics Occurs Independently of Their Effects on Translation Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans Melanins Protect Sporothrix brasiliensis and Sporothrix schenckii from the Antifungal Effects of Terbinafine Chemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformans Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase In vitro additive interaction between ketoconazole and antimony against intramacrophage Leishmania (Leishmania) amazonensis amastigotes Influence of First-Line Antibiotics on the Antibacterial Activities of Acetone Stem Bark Extract of Acacia mearnsii De Wild. against Drug-Resistant Bacterial Isolates.Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition.In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors Structural Basis of Transcription Inhibition by CBR Hydroxamidines and CBR Pyrazoles.The licorice pentacyclic triterpenoid component 18β-glycyrrhetinic acid enhances the activity of antibiotics against strains of methicillin-resistant Staphylococcus aureus.Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens.In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.Polymicrobial Ventilator-Associated Pneumonia: Fighting In Vitro Candida albicans-Pseudomonas aeruginosa Biofilms with Antifungal-Antibacterial Combination Therapy.Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance.In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase.In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods.Repurposing auranofin for the treatment of cutaneous staphylococcal infections.Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions In vitro susceptibility testing in Aspergillus species: an update.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Combination therapy for the treatment of pulmonary mold infections.Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.Identification and Mode of Action of a Plant Natural Product Targeting Human Fungal Pathogens.Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.Unraveling the biology of a fungal meningitis pathogen using chemical genetics.The joint in vitro action of polymyxin B and miconazole against pathogens associated with canine otitis externa from three European countries.Chemical space guided discovery of antimicrobial bridged bicyclic peptides against Pseudomonas aeruginosa and its biofilms.

P2860

Q27684447-F5D99E7C-9D99-463F-9699-5F509286771B Q28487653-BA52B348-59C4-4ABA-8DD0-9E3172D43C7C Q28551102-52ACA97F-CFDA-4F8B-8CDF-4FB1A8FA3770 Q28554238-7FC31112-05B8-4691-8C0B-93ACF1EBC9A8 Q30303549-46A4F161-DDE2-4B89-AAA2-92D95A512309 Q33853773-1DA322C9-2AAC-4AC9-821D-40FD37E0BFED Q33914695-683EF810-D6D8-4AA6-B48B-CE64360D86EC Q34431951-7CA3ED1A-96A2-4293-9F8E-C24D2BBECA5D Q34554996-BB760D1D-6432-48A3-81A5-7F7B818F1EFB Q34596443-E46648EA-2573-40ED-A021-128BDABDDCCC Q35152853-51583EB6-07DA-4705-8824-28B3B37A154E Q35243846-B42FDD5B-8AEC-432C-BAE1-AC4AB7D2E5BE Q35697121-F4B1C9A3-D161-405C-ADB8-DD2E54CD1C4F Q35896916-C6484D31-FDE6-456E-B8F9-BF25DB71B2D3 Q35943844-16A0345D-2E05-4A81-99BD-E1F11AF56761 Q36171554-680DFBCC-E843-4EAE-8A18-5E7F61BBF58D Q36180580-9EFC1100-70D8-4491-AE66-193D8452A183 Q36257537-36D4BCD4-F7B1-4493-A5FD-7D2BA4B897E2 Q36360329-36182834-5E66-4231-AD94-C4C7DB72DBBB Q36410455-83866595-2B4E-41F5-963D-1F4E1C7EFB19 Q36558484-9DF55059-68AE-41B7-AD37-D602B78DFA61 Q36666497-372C5A45-C1E8-4EDA-9AAF-D70A5E2F5796 Q36667135-202B3667-E0CC-486B-B1DD-9948C3F7C9D0 Q36689702-E59F0FEB-132F-4063-B522-1C668AD6D70F Q37246227-3CA5B370-5B43-42A9-AD08-4913C1D3B861 Q37263780-B776C2ED-3C37-489C-A048-F42DE6CEDED5 Q37742178-9B8EF532-6418-479C-A0EA-E6B5DA00A968 Q38681635-A1782740-F4E2-47F1-9091-9086223459A3 Q38806932-801AF82D-E2F2-4E89-AE7A-D1E335C43C1F Q39269795-8C9E477C-579B-46A5-B6F3-90CD93EE1805 Q40094165-1A42D4B5-1063-4A74-ACCB-50310E7E84A6 Q40148508-DEA916CA-AE6D-4106-B988-97C6022B17AB Q40153501-32BFC108-E8E1-4259-90AB-8CAB4F070FDF Q40444230-E66F96C1-B9C4-4EC1-A858-5B7FA48DF266 Q40569093-798710D0-83D1-42DF-ABEF-AFA49B1E64E0 Q40663341-E0199A52-38A4-40C5-A040-A17740E6A2C9 Q40936437-AB18177B-ADEA-4221-BD28-35A2921ADEDE Q41652452-F64A1F10-95F3-41D0-8EB7-CDAE60159D71 Q41815412-891D14F0-C0A2-4A77-899D-2D9367BAA505 Q44157129-4646977F-FC7B-43D5-9AE0-22F30C00D0F4

P2860

Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillu

Item

http://www.wikidata.org/entity/Q33517581

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu